Klinická farmakologie a farmacie – 2/2018

www.klinickafarmakologie.cz  / Klin Farmakol Farm 2019; 33(2): 20–23 / KLINICKÁ FARMAKOLOGIE A FARMACIE 23 HLAVNÍ TÉMA Periferní myorelaxancia v moderní anesteziologii LITERATURA 1. Griffith H, Johnson GE. The Use of Curare in Gene‑ ral Anesthesia. Anesthesiology, 1942. 3(4): 418–420. doi:10.1097/00000542-194207000-00006. 2. Gjsenbergh F, Ramael S, Houwing N, van Iersel T. First hu‑ man exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005 Oct; 103(4): 695–703. 3. Adamus M, Černý V, Cvachovec K, et al. Zásady bezpečné anesteziologické péče. Anesteziologie a intenzivní medicí‑ na, 2018, 29(2): 107–110. 4. Adamus M, Herold I, Cvachovec K, Ševčík P, Černý V. Sva‑ lová relaxace během celkové anestezie v České republice 2010 – Jednodenní prospektivní observační dotazníková stu‑ die. Anesteziologie a intenzivní medicína. 2011; 22(2): 82–99. 5. Klucka J, Kosinova M, Krikava I, Stoudek R, Toukalkova M, Stourac P. Residual Neuromuscular Blockade in Paediatric Anaesthesia. British Journal of Anaesthesia. 2019. Jan; 122(1): e1–e2. doi: 10.1016/j.bja.2018. 10. 001 6. Fortier LP, McKeen D, Turner K, et al. The RECITE study: a Ca‑ nadian prospective, multicenter study of the incidence and severity of residual neuromuscular blockade. Anesth Analg. 2015; 121: 366–372. 7. Claudius C, Garvey LH, Viby‑Mogensen J. The undesirable effects of neuromuscular blocking drugs. Anaesthesia 2009; 64(Suppl. 1): 10–21. 8. Eikermann M, Fassbender P, Malhotra A, et al. Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. Anesthesio‑ logy 2007; 107: 621–629. 9. Beemer GH, Bjorksten AR, Dawson PJ, et al. Determinants of the reversal time of competitive neuromuscular block by anticholinesterases. Br J Anaesth 1991; 66: 469–475. 10. Stourac P, Krikava I, Seidlova J, Strazevska E, Huser M, Hru‑ ban L, Janku P, Gal R. Sugammadex in a parturient with myo‑ tonic dystrophy. Br J Anaesth. 2013 Apr; 110(4): 657–658. doi: 10.1093/bja/aet037. 11. Saricicek V, Sahin L, Bulbul F, Ucar S, Sahin M. Does rocuronium‑sugammadex reduce myalgia and heada‑ che after electroconvulsive therapy in patients with ma‑ jor depression? J ECT. 2014 Mar; 30(1): 30–34. doi: 10.1097/ YCT.0b013e3182972bd2. 12. Lee C. Goodbye suxamethonium! Anaesthesia. 2009 Mar; 64(Suppl 1): 73–81. doi: 10.1111/j.1365-2044.2008.05873.x. 13. Stourac P, Adamus M, Seidlova D, et al. Low‑dose or high‑dose rocuronium reversed with neostigmine or sugamma‑ dex for cesarean delivery anesthesia: A randomized contro‑ lled non‑inferiority trial of time to tracheal intubation and extubation. Anesth Analg. 2016 May; 122(5): 1536–1545. doi: 10.1213/ANE.0000000000001197. 14. Kosinova M, Stourac P, Adamus M, et al. Rocuronium ver‑ sus suxamethonium for rapid sequence induction of gene‑ ral anaesthesia for caesarean section: influence on neona‑ tal outcomes. Int J Obstet Anesth. 2017 Nov; 32: 4–10. doi: 10.1016/j.ijoa.2017. 05. 001. Epub 2017 May 10.